Catalent St Petersburg is the US Center of Excellence for Softgel and Oral Liquid Development. Rx and OTC Softgel & Oral Liquid Dosage Form Development and Manufacturing from Pre-clinical to Commercial. Integrated offering such as OptiForm® Solution Suite. Commercial capability to serve major and minor markets across globe. 100+ Dedicated R&D team (Analytical, Product Development and Project Management). 37 GMP manufacturing lines
Worldwide regulatory approval (EMA, FDA, ANVISA, PMDA, MOH).
Catalent positions itself as a leading partner in drug development, delivery, and supply for drugs, biologics, and consumer health products. The company has extensive capabilities and a significant global presence, with over 50 sites on four continents and more than 2,500 scientists and technicians across 25 R&D teams. Catalent has created over 70 billion doses, has 1,400 active development programs, and has assisted in 50% of FDA approvals in the last 10 years. Additionally, Catalent has a strong history of innovation, including the development of technologies like Zydis® and GPEx®. Their mission and vision emphasize their commitment to being the most trusted, reliable, and innovative partner in the industry.
Catalent supports over 1,500 partner programs and launches over 150 new products annually, indicating a robust and expanding customer base and strong client relationships. They provide services to pharma, biotech, and consumer health customers, and are involved in the development, launch, and full life-cycle supply of products. Catalent supports the acceleration of development programs and the launch of more than a hundred new products annually, supplying billions of doses of treatments each year.
